• E-mailmari.halle@uib.no
  • Visitor Address
    Jonas Lies vei 72
    5053 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

I hold a PhD from the University of Bergen on molecular alterations suggesting new treatment strategies in uterine carcinomas. I am currently a researcher in the Bergen Gynecological Cancer Research Group, working on gynecological cancer. My main focus is to characterize targetable molecular alterations driving aggressive uterine carcinoma. Currently, I am working on a study comparing radiomic features from whole tumor segmented magnetic resonance imaging (MRI) scans to genomic profiles. This radiogenomic approach will detect novel prognosticators for disease outcome and may reveal new treatment strategies in cervical cancer.

Academic article
  • Show author(s) (2024). Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer. Gynecologic Oncology. 110-117.
  • Show author(s) (2023). Visceral fat percentage for prediction of outcome in uterine cervical cancer. Gynecologic Oncology. 62-68.
  • Show author(s) (2023). Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease. EBioMedicine. 14 pages.
  • Show author(s) (2023). MRI-based radiomic signatures for pretreatment prognostication in cervical cancer. Cancer Medicine.
  • Show author(s) (2022). What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer? Insight into Imaging. 1-14.
  • Show author(s) (2022). Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. British Journal of Cancer. 647-655.
  • Show author(s) (2022). Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer. European Radiology. 6444-6455.
  • Show author(s) (2022). Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. Nature Communications. 1-17.
  • Show author(s) (2022). Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. Cancers. 1-16.
  • Show author(s) (2022). APOBEC3A/B deletion polymorphism and endometrial cancer risk. Cancer Medicine.
  • Show author(s) (2021). Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. Biomarkers. 302-308.
  • Show author(s) (2021). High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. International Journal of Molecular Sciences. 17 pages.
  • Show author(s) (2021). Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers. 15 pages.
  • Show author(s) (2021). Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. NPJ GENOMIC MEDICINE.
  • Show author(s) (2021). A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology. 12 pages.
  • Show author(s) (2021). A gene signature identifying CIN3 regression and cervical cancer survival. Cancers. 1-18.
  • Show author(s) (2021). A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer. 1690-1698.
  • Show author(s) (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Show author(s) (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Show author(s) (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Show author(s) (2019). PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Show author(s) (2019). Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Show author(s) (2019). Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Show author(s) (2018). The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. European Journal of Hybrid Imaging. 1-14.
  • Show author(s) (2018). Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Show author(s) (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Show author(s) (2017). PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Show author(s) (2017). MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer. 1-6.
  • Show author(s) (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Show author(s) (2017). Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Show author(s) (2017). Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Show author(s) (2016). Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Show author(s) (2016). The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Show author(s) (2016). The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumour Biology. 10697-10702.
  • Show author(s) (2016). Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clinical Cancer Research. 513-523.
  • Show author(s) (2016). Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Show author(s) (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Show author(s) (2015). Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Show author(s) (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Show author(s) (2014). The evolution and functional divergence of the beta-carotene oxygenase gene family in teleost fish-Exemplified by Atlantic salmon. Gene. 268-274.
  • Show author(s) (2014). Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Show author(s) (2014). Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Show author(s) (2014). Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • Show author(s) (2014). Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology, Research and Practice. 774-778.
  • Show author(s) (2014). Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Show author(s) (2014). Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Show author(s) (2014). Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Show author(s) (2014). High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Show author(s) (2014). Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • Show author(s) (2014). Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Show author(s) (2013). Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Show author(s) (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 pages.
  • Show author(s) (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • Show author(s) (2012). High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Show author(s) (2012). Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
Reader opinion piece
  • Show author(s) (2012). Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
Doctoral dissertation
  • Show author(s) (2017). Molecular alterations suggesting new treatment strategies in uterine carcinomas.
  • Show author(s) (2023). Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595] (eBioMedicine (2023) 92, (S2352396423001603), (10.1016/j.ebiom.2023.104595)). EBioMedicine.

More information in national current research information system (CRIStin)